Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2024-04-27 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2024-04-27 English
ARS
Annual Report
2024-04-25 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is identified as a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as 'Definitive Additional Materials' related to the proxy statement. Proxy statements and related materials are used to provide shareholders with information and solicit votes for meetings. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is short and it is not a full annual report or other financial report. Therefore, the correct classification is PSI with high confidence.
2024-04-25 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 17, 2024, reporting an amendment and restatement of the company's bylaws. The content focuses on corporate governance changes, specifically amendments to the bylaws related to stockholder proposals, proxy rules, and procedural updates. There are no financial statements or earnings data presented. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is a regulatory filing reporting a governance-related event. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 5270 characters, which is sufficient to contain substantive content rather than a mere announcement. Hence, it is not a Report Publication Announcement (RPA).
2024-04-19 English
PRIMARY DOCUMENT
Director's Dealing
2024-03-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.